Table 3.
Characteristics of COVID-19 patients who developed IFIs clustered by fungus genera.
| Invasive Candidiasis | N = 6 |
|---|---|
| ICU admission *, n (%) | 4 (67) |
| Severe COVID-19 **, n (%) | 5 (83) |
| Tocilizumab, n (%) | 0 (0) |
| Length of Stay (days), mean | 55 |
| Overall mortality, n (%) | 2 (33) |
| Pneumocystis jirovecii Pneumonia (PJP) | N = 7 |
| ICU admission *, n (%) | 2 (29) |
| Severe COVID-19 **, n (%) | 2 (29) |
| Hematologic malignancy, n (%) | 1 (14) |
| Immunotherapy, n (%) | 1 (14) |
| Tocilizumab, n (%) | 0 (0) |
| Cumulative steroid dosage (prednisone equivalent, mg) *, mean | 1301 |
| Lymphopenia, n (%) | 5 (71) |
| CD4+ < 200 n/µL, n (%) | 4/6 (67) |
| HIV infection, n (%) | 0 (0) |
| AIDS, n (%) | 0 (0) |
| Length of Stay (days), mean | 43 |
| Overall mortality, n (%) | 0 (0) |
| Post COVID-19 Invasive Pulmonary Aspergillosis (IPA) | N = 3 |
| ICU admission *, n (%) | 2 (67) |
| Severe COVID-19 **, n (%) | 2 (67) |
| Hematologic malignancy, n (%) | 0 (0) |
| Immunotherapy, n (%) | 0 (0) |
| Tocilizumab, n (%) | 0 (0) |
| Cumulative steroid dosage (prednisone equivalent, mg) *, mean | 1026 |
| Lymphopenia, n (%) | 3 (100) |
| CD4+ <200 n/µL, n (%) | 1/2 (50) |
| HIV infection, n (%) | 0 (0) |
| AIDS, n (%) | 0 (0) |
| Length of Stay (days), mean | 60 |
| Overall mortality, n (%) | 1 (33) |
* Prior to IFI diagnosis for the IFIs groups or at hospital discharge for the control population. ** Severe disease defined by 5 to 7 points (8-point WHO-OSCI) at the time of IFI diagnosis for the IFIs groups or at any stage for the control population.